Related Experiment Video
Updated: Jul 13, 2026
09:58
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Multilayer Validation Reveals a Glia-Associated Secretome Signature in Temporal Lobe Epilepsy.
Yang Dai1,2,3, Zesheng Li1,2,3, Quanlei Liu1,2,3
1Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Journal of Molecular Neuroscience : MN
|July 11, 2026
Summary
Researchers identified six key proteins in cerebrospinal fluid (CSF) as potential biomarkers for temporal lobe epilepsy (TLE). Elevated levels of five proteins and reduced transthyretin (TTR) were observed in TLE patients, suggesting microglial activation in epilepsy.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Molecular Biology
Background:
- Epilepsy diagnosis lacks reliable cerebrospinal fluid (CSF) biomarkers despite known molecular alterations.
- Existing multi-omics studies highlight molecular changes but few clinically accessible biomarkers exist.
Purpose of the Study:
- Identify and validate CSF biomarkers for temporal lobe epilepsy (TLE).
- Investigate molecular alterations, including inflammation and glial activation, linked to TLE progression.
Main Methods:
- Utilized Kainic Acid (KA)-induced mouse model and single-cell RNA sequencing.
- Analyzed public transcriptomic data and validated candidate biomarkers in mouse and human datasets.
- Quantified protein levels in human CSF using ELISA and employed machine learning for diagnostic performance evaluation.
Main Results:
- Six proteins (CXCL10, TTR, APOE, APOD, LGALS3BP, LYZ) were dysregulated in TLE patient CSF.
- CXCL10, APOE, APOD, LGALS3BP, and LYZ were elevated; TTR was reduced (p < 0.001).
- Machine learning models showed promising classification, with TTR and CXCL10 as key features; CXCL10 correlated with seizure frequency.
Conclusions:
- Microglial activation and glia-related alterations are associated with TLE progression.
- Secreted proteins like TTR and CXCL10 show potential as CSF biomarkers for TLE.
- These findings support further translational investigation of CSF biomarkers for epilepsy.
